# FDA 483 - Shore Institute For Reproductive Medicine, P.C. - March 29, 2011

Source: https://www.globalkeysolutions.net/records/483/shore-institute-for-reproductive-medicine-pc/3e465f41-d13b-474c-9d47-6a8a9e2b2080

> FDA 483 for Shore Institute For Reproductive Medicine, P.C. on March 29, 2011. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Shore Institute For Reproductive Medicine, P.C.
- Inspection Date: 2011-03-29
- Product Type: biologics
- Office Name: New Jersey District Office
- Summary: An FDA inspection of Shore Institute For Reproductive Medicine, P.C. in Lakewood, NJ, from March 23-29, 2011, revealed a significant deficiency in donor screening practices. The firm failed to adequately screen donors for risk factors of communicable diseases, specifically regarding the risk of contracting CJD or vCJD from blood transfusions in France.

## Related Documents

- [483 - 2008-03-05](https://www.globalkeysolutions.net/records/483/shore-institute-for-reproductive-medicine-pc/67bd7cf3-83fe-474d-aab7-f6a263d6d97e)

## Related Officers

- [investigator](https://www.globalkeysolutions.net/people/sarah-m-forney/3d68a56a-3c2f-4606-8e98-03808281842b)

Company: https://www.globalkeysolutions.net/companies/shore-institute-for-reproductive-medicine-pc/0da28d4f-797f-44de-91b9-1fefa34d687a

Office: https://www.globalkeysolutions.net/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248